BlackBio, dedicated to developing and marketing new solutions for personalized medicine through disruptive technologies, has obtained CE Marking for BlackLight Sepsis Kit, intended for a fast easy‐to‐use and cost competitive diagnostic test, allowing rapid identification of bacteria causing infection.

Compendia Bioscience, Inc. today announced the award of $1.3 million in SBIR Fast Track funds to incorporate micro-RNA data and analyses into the Oncomine platform.

Source: Compendia

Platform components include a SpotBot® 3 Protein Microarrayer or NanoPrint™ Protein Edition Microarrayer with cooled platen and humidity control, a SpotWare™ Colorimetric Microarray Scanner, a Microarray High-Speed Centrifuge, a High-Throughput Wash Station, a Microarray Reaction Cassette, BlockIt™ Blocking Buffer, SuperNitro Microarray Substrate Slides, and an Alkaline Phosphatase Labeling Kit.

Eppendorf AG and Nanosphere, Inc. (Nasdaq:NSPH) announced today that Nanosphere has acquired certain patents and patent rights of Eppendorf on a global basis for $4 million, while providing a limited license back to service existing Eppendorf customers and licenses previously issued that relate to the purchased patents and patent rights. As part of the transaction, the companies settled a patent litigation dispute.

OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today its 2010 half-year results and its new strategy.

Source: Oncomethylome

Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG(R) Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

Agilent Technologies Inc. (NYSE: A) today introduced the SureSelect Human All Exon v2 Target Enrichment kit, which was developed in close collaboration with the Broad Institute of MIT and Harvard. The kit, the 15th SureSelect product in Agilent’s portfolio, is a single tube assay that allows researchers to streamline experiments by sequencing the expressed genome while discarding regions not of interest.

NIMR scientists have found a unique pattern of gene activity, or immune signature, in the blood of patients with tuberculosis. The research is published in Nature.

Agilent Technologies Inc. (NYSE: A) and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders. Dr. Hartung recently was named a leading toxicologist by the science journal Nature.

Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG(R) Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

Agilent Technologies Inc. (NYSE: A) today announced that a group of researchers from the University of California, Davis, has made a significant discovery: human breast milk contains an unexpected abundance of sugars that coats the lining of infants’ intestines, protecting it from noxious bacteria. Results of the research, which used Agilent technology, were published in this month’s Proceedings of the National Academy of Sciences of the United States of America.

Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced it has donated the first commercial unit of its newly launched MAGPIX(R) instrument to Professor Peter Siba and his scientific team at the Papua New Guinea Institute of Medical Research. The instrument will be used onsite in Papua New Guinea to progress malaria research led by Dr. Peter Zimmerman, Professor of International Health, Genetics and Biology at the Center for Global Health and Diseases at Case Western Reserve University. Malaria has long been a leading cause of death in Papua New Guinea and is a significant public health challenge in the nation.

Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today reported financial results for the second quarter ended June 30, 2010.

Source: Vermillion

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

Illumina, Inc. (NASDAQ:ILMN) today announced the creation of the Illumina Genome Network, a global partnership designed to link researchers interested in conducting large-scale whole human genome sequencing projects with leading institutions that can perform such projects using Illumina sequencing. The Genome Network will provide researchers who do not have access to high-quality, next-generation sequencing technology an economical and dependable way to complete their sequencing projects.